Document is current
Any future updates will be listed below
-
Authors
Ellis, Anne K.
Mack, Douglas P.
Gagnon, Rémi
Hammerby, Eva https://orcid.org/0000-0001-9418-264X
Gosain, Sheena
-
Funding
Funding for this research was provided by:
ALK-Abelló A/S
- License Information
-
More Information
Article History
Received: 20 October 2022
Accepted: 2 January 2023
First Online: 18 January 2023
Declarations
:
: Not applicable.
: Not applicable.
: A.K. Ellis has participated in advisory boards for Abbvie, ALK-Abelló, AstraZeneca, Bausch Health, Circassia Ltd, GlaxoSmithKline, LEO Pharma, Johnson & Johnson, Merck, Miravo, Mylan, Novartis, Pediapharm and Pfizer, has been a speaker for ALK, Aralez, AstraZeneca, Bausch Health, Boehringer-Ingelheim, CACME, Meda, Medexus, Mylan, Merck, Novartis,, Pfizer, The ACADEMY, and Takeda. Her institution has received research grants from AstraZeneca, Bayer, LLC, Circassia Ltd, Green Cross Pharmaceuticals, GlaxoSmithKline, Sun Pharma, Merck, Novartis, Pfizer, Regeneron and Sanofi. She has also served as an independent consultant to Allergy Therapeutics, Bayer, LLC, Ora Inc., and Regeneron in the past. D. Mack has provided consultation and speaker services for Pfizer, Aimmune, Kaleo, Merck, Covis and Pediapharm, and has been part of an advisory board for Pfizer and Bausch Health. He sits on the editorial board for the Journal of Food Allergy and has served as an investigator for ALK-Abelló. R. Gagnon has served as a speaker and/or advisor for ALK-Abello, AstraZeneca, Bausch Health, CSL Behring, GlaxoSmithKline, Merck, Novartis, Pfizer, Sanofi, and Shire, and Valeo Pharma, and served as an investigator for AstraZeneca, Amgen, Biocryst, DBV, GlaxoSmithKline, Green Cross Pharmaceuticals, Merck, Novartis, Pharvaris, Regeneron, Shire, Stallergenes, and Sanofi Genzyme/Regeneron. S. Gosain is an employee of PDCI Market Access Inc., which provided contracted services to ALK- Abelló A/S. E. Hammerby is an employee of ALK- Abelló A/S.
